Staghorn, you have absolutely nailed it. It is because of the 'stability' of the plasma fractionation business that analysts view PLI to be a low risk/high return stock. PPPS is best of class technology and offers huge potential for growth in two areas.

First, PPPS can selectively extract valuable therapeutic proteins at will. To date, PLI has ligands to extract plasminogen, IVIG, Factor VIII, AAT, fibriogen, various hyper-immunes, albumin and others that may have been developed with CNBG. However there are dozens more plasma therapeutic proteins that can be extracted, many of which will have orphan drug status. It will be interesting to see which proteins PLI will target in the next round of development. It takes about 12 months to find the best binding ligand and incorporate into the PPPS process.

Secondly, most countries wish to become self sufficient in plasma protein products. I have talked about the opportunity in Canada ( at least a 400 000 litre capacity plant) but other countries in Asia and Latin America also wish to achieve self sufficiency. As the plants in Laval and China come onstream, I am sure that there will be investors in a number countries knocking on PLI's door to licence the PPPS technology. 

The first round of commercialisation of the PPPS technology and the above plasma proteins involving the Laval plant, CNBG and Hematech has got to be worth $5+/share, limited only by production capacity. The second round of commercialisation as the number of plasma proteins is increased and more PPPS plants are built around the world is likely to be worth much more. Rest assured, some day one of the Big Fractionators is going to take a close look at PLI because the technology is that good. But, it is also highly disruptive  and you know what that means.

I too will get excited when the sp hits $3 but frankly I will not take any money off the table until the sp hits $10+. This is based on the plasma business alone. If 4050 proves efficient in early clinical trials, partnership deals are signed and the drug eventually commercialised in a number of applications then the sky will be the limit, delivering returns which will be a multiple of those expected from the protein division. hard to believe but very possible!

You can understand why I do not get too excited by the volatility in the sp. If the sp drops by 30%, I know it is going to snap back in due course. This is why I advocate for people to hold on to their shares and stay the course as the rewards are going to be tremendous!